Prediction of the overall renal tubular secretion and hepatic clearance of anionic drugs and a renal drug-drug interaction involving organic anion transporter 3 in humans by in vitro uptake experiments

Drug Metabolism and Disposition

Volumn 39, Issue 6, 2011, Pages 1031-1038

  Watanabe, Takao ^a   Kusuhara, Hiroyuki ^a   Watanabe, Tomoko ^a   Debori, Yasuyuki ^a   Maeda, Kazuya ^a   Kondo, Tsunenori ^b   Nakayama, Hideki ^b   Horita, Shigeru ^b   Ogilvie, Brian W ^c   Parkinson, Andrew ^c   Hu, Zhuohan ^d   Sugiyama, Yuichi ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

^c XenoTech LLC   (United States)

^d Research Institute for Liver Diseases Shanghai Co Ltd   (China)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOHIPPURIC ACID; ATORVASTATIN; CANDESARTAN; CERIVASTATIN; DRUG METABOLITE; FEXOFENADINE; FLUINDOSTATIN; GEMFIBROZIL; GEMFIBROZIL GLUCURONIDE; GEMFIBROZIL M3; METHOTREXATE; OLMESARTAN; ORGANIC ANION TRANSPORTER 3; PENICILLIN G; PITAVASTATIN; PRAVASTATIN; ROSUVASTATIN; TRICHLORMETHIAZIDE; UNCLASSIFIED DRUG; VALSARTAN;

ARTICLE; CONTROLLED STUDY; CRYOPRESERVATION; DRUG CLEARANCE; DRUG INHIBITION; DRUG TRANSPORT; DRUG UPTAKE; HUMAN; HUMAN CELL; HUMAN TISSUE; IC 50; IN VITRO STUDY; KIDNEY SLICE; KIDNEY TUBULE EXCRETION; LIVER CELL; LIVER CLEARANCE; PREDICTION; PRIORITY JOURNAL; PROTEIN FUNCTION; RELIABILITY;

ANIONS; CELLS, CULTURED; DRUG INTERACTIONS; HEPATOCYTES; HUMANS; KIDNEY TUBULES; LIVER; METABOLIC CLEARANCE RATE; ORGANIC ANION TRANSPORTERS, SODIUM-INDEPENDENT; PHARMACEUTICAL PREPARATIONS; PREDICTIVE VALUE OF TESTS; SUBSTRATE SPECIFICITY;

ANIMALIA;

EID: 79956089974     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.110.036129     Document Type: Article

References (38)

1. Adolph EF (1949) Quantitative relations in the physiological constitutions of mammals. Science 109:579-585.
2. Backman JT, Kyrklund C, Neuvonen M, and Neuvonen PJ (2002) Gemfibrozil greatly increases plasma concentrations of cerivastatin. Clin Pharmacol Ther 72:685-691. (Pubitemid 36021007)
3. Boxenbaum H (1982) Interspecies scaling, allometry, physiological time, and the ground plan of pharmacokinetics. J Pharmacokinet Biopharm 10:201-227.
4. Chiba M, Ishii Y, and Sugiyama Y (2009) Prediction of hepatic clearance in human from in vitro data for successful drug development. AAPS J 11:262-276.
5. Davies B and Morris T (1993) Physiological parameters in laboratory animals and humans. Pharm Res 10:1093-1095. (Pubitemid 23211439)
6. Fujino H, Saito T, Ogawa S, and Kojima J (2005) Transporter-mediated influx and efflux mechanisms of pitavastatin, a new inhibitor of HMG-CoA reductase. J Pharm Pharmacol 57:1305-1311. (Pubitemid 41545896)
7. Hasannejad H, Takeda M, Taki K, Shin HJ, Babu E, Jutabha P, Khamdang S, Aleboyeh M, Onozato ML, Tojo A, et al. (2004) Interactions of human organic anion transporters with diuretics. J Pharmacol Exp Ther 308:1021-1029. (Pubitemid 38263978)
8. Hasegawa M, Kusuhara H, Endou H, and Sugiyama Y (2003) Contribution of organic anion transporters to the renal uptake of anionic compounds and nucleoside derivatives in rat. J Pharmacol Exp Ther 305:1087-1097. (Pubitemid 36617987)
9. Hirouchi M, Kusuhara H, Onuki R, Ogilvie BW, Parkinson A, and Sugiyama Y (2009) Construction of triple-transfected cells [organic anion-transporting polypeptide (OATP) 1B1/multidrug resistance-associated protein (MRP) 2/MRP3 and OATP1B1/MRP2/MRP4] for analysis of the sinusoidal function of MRP3 and MRP4. Drug Metab Dispos 37:2103-2111.
10. Ito K, Iwatsubo T, Kanamitsu S, Ueda K, Suzuki H, and Sugiyama Y (1998) Prediction of pharmacokinetic alterations caused by drug-drug interactions: metabolic interaction in the liver. Pharmacol Rev 50:387-412.
11. Iwatsubo T, Hirota N, Ooie T, Suzuki H, and Sugiyama Y (1996) Prediction of in vivo drug disposition from in vitro data based on physiological pharmacokinetics. Biopharm Drug Dispos 17:273-310. (Pubitemid 26176731)
12. Kilford PJ, Stringer R, Sohal B, Houston JB, and Galetin A (2009) Prediction of drug clearance by glucuronidation from in vitro data: use of combined cytochrome P450 and UDP-glucuronosyltransferase cofactors in alamethicin-activated human liver microsomes. Drug Metab Dispos 37:82-89.
13. Kusuhara H and Sugiyama Y (2009) In vitro-in vivo extrapolation of transporter-mediated clearance in the liver and kidney. Drug Metab Pharmacokinet 24:37-52.
14. Kyrklund C, Backman JT, Neuvonen M, and Neuvonen PJ (2003) Gemfibrozil increases plasma pravastatin concentrations and reduces pravastatin renal clearance. Clin Pharmacol Ther 73:538-544. (Pubitemid 37249124)
15. Mahmood I (1998) Interspecies scaling of renally secreted drugs. Life Sci 63:2365-2371.
16. Matsushima S, Maeda K, Inoue K, Ohta KY, Yuasa H, Kondo T, Nakayama H, Horita S, Kusuhara H, and Sugiyama Y (2009) The inhibition of human multidrug and toxin extrusion 1 is involved in the drug-drug interaction caused by cimetidine. Drug Metab Dispos 37:555-559.
17. Nakagomi-Hagihara R, Nakai D, and Tokui T (2007) Inhibition of human organic anion transporter 3 mediated pravastatin transport by gemfibrozil and the metabolites in humans. Xenobiotica 37:416-426. (Pubitemid 46572887)
18. Nozaki Y, Kusuhara H, Kondo T, Hasegawa M, Shiroyanagi Y, Nakazawa H, Okano T, and Sugiyama Y (2007a) Characterization of the uptake of organic anion transporter (OAT) 1 and OAT3 substrates by human kidney slices. J Pharmacol Exp Ther 321:362-369. (Pubitemid 46456974)
19. Nozaki Y, Kusuhara H, Kondo T, Iwaki M, Shiroyanagi Y, Nakayama H, Horita S, Nakazawa H, Okano T, and Sugiyama Y (2007b) Species difference in the inhibitory effect of nonsteroidal anti-inflammatory drugs on the uptake of methotrexate by human kidney slices. J Pharmacol Exp Ther 322:1162-1170.
20. Roberts MS and Rowland M (1986) A dispersion model of hepatic elimination: 1. Formulation of the model and bolus considerations. J Pharmacokinet Biopharm 14:227-260.
21. Obach RS (1999) Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: an examination of in vitro half-life approach and nonspecific binding to microsomes. Drug Metab Dispos 27:1350-1359.
22. Okerholm RA, Keeley FJ, Peterson FE, and Glazko AJ (1976) The metabolism of gemfibrozil. Proc R Soc Med 69 (Suppl 2):11-14.
23. Sato M, Iwanaga T, Mamada H, Ogihara T, Yabuuchi H, Maeda T, and Tamai I (2008) Involvement of uric acid transporters in alteration of serum uric acid level by angiotensin II receptor blockers. Pharm Res 25:639-646. (Pubitemid 351357726)
24. Shitara Y, Hirano M, Sato H, and Sugiyama Y (2004) Gemfibrozil and its glucuronide inhibit the organic anion transporting polypeptide 2 (OATP2/OATP1B1:SLC21A6)-mediated hepatic uptake and CYP2C8-mediated metabolism of cerivastatin: analysis of the mechanism of the clinically relevant drug-drug interaction between cerivastatin and gemfibrozil. J Pharmacol Exp Ther 311:228-236. (Pubitemid 39287802)
25. Shitara Y, Itoh T, Sato H, Li AP, and Sugiyama Y (2003) Inhibition of transporter-mediated hepatic uptake as a mechanism for drug-drug interaction between cerivastatin and cyclosporin A. J Pharmacol Exp Ther 304:610-616. (Pubitemid 36152336)
26. Stringer R, Nicklin PL, and Houston JB (2008) Reliability of human cryopreserved hepatocytes and liver microsomes as in vitro systems to predict metabolic clearance. Xenobiotica 38:1313-1329.
27. Tahara H, Kusuhara H, Chida M, Fuse E, and Sugiyama Y (2006a) Is the monkey an appropriate animal model to examine drug-drug interactions involving renal clearance? Effect of probenecid on the renal elimination of H2 receptor antagonists. J Pharmacol Exp Ther 316:1187-1194. (Pubitemid 43345293)
28. Tahara H, Kusuhara H, Endou H, Koepsell H, Imaoka T, Fuse E, and Sugiyama Y (2005b) A species difference in the transport activities of H2 receptor antagonists by rat and human renal organic anion and cation transporters. J Pharmacol Exp Ther 315:337-345. (Pubitemid 41380529)
29. Tahara H, Kusuhara H, Maeda K, Koepsell H, Fuse E, and Sugiyama Y (2006b) Inhibition of oat3-mediated renal uptake as a mechanism for drug-drug interaction between fexofenadine and probenecid. Drug Metab Dispos 34:743-747.
30. Tahara H, Shono M, Kusuhara H, Kinoshita H, Fuse E, Takadate A, Otagiri M, and Sugiyama Y (2005a) Molecular cloning and functional analyses of OAT1 and OAT3 from cynomolgus monkey kidney. Pharm Res 22:647-660. (Pubitemid 40603263)
31. Watanabe T, Kusuhara H, Maeda K, Kanamaru H, Saito Y, Hu Z, and Sugiyama Y (2010a) Investigation of the rate-determining process in the hepatic elimination of HMG-CoA reductase inhibitors in rats and humans. Drug Metab Dispos 38:215-222.
32. Watanabe T, Kusuhara H, Maeda K, Shitara Y, and Sugiyama Y (2009a) Physiologically based pharmacokinetic modeling to predict transporter-mediated clearance and distribution of pravastatin in humans. J Pharmacol Exp Ther 328:652-662.
33. Watanabe T, Kusuhara H, and Sugiyama Y (2010b) Application of physiologically based pharmacokinetic modeling and clearance concept to drugs showing transporter-mediated distribution and clearance in humans. J Pharmacokinet Pharmacodyn 37:575-590.
34. Watanabe T, Maeda K, Kondo T, Nakayama H, Horita S, Kusuhara H, and Sugiyama Y (2009b) Prediction of the hepatic and renal clearance of transporter substrates in rats using in vitro uptake experiments. Drug Metab Dispos 37:1471-1479.
35. Windass AS, Lowes S, Wang Y, and Brown CD (2007) The contribution of organic anion transporters OAT1 and OAT3 to the renal uptake of rosuvastatin. J Pharmacol Exp Ther 322:1221-1227. (Pubitemid 47295808)
36. Yamada A, Maeda K, Kamiyama E, Sugiyama D, Kondo T, Shiroyanagi Y, Nakazawa H, Okano T, Adachi M, Schuetz JD, et al. (2007) Multiple human isoforms of drug transporters contribute to the hepatic and renal transport of olmesartan, a selective antagonist of the angiotensin II AT1-receptor. Drug Metab Dispos 35:2166-2176. (Pubitemid 350146202)
37. Yamaoka K, Tanigawara Y, Nakagawa T, and Uno T (1981) A pharmacokinetic analysis program (multi) for microcomputer. J Pharmacobiodyn 4:879-885. (Pubitemid 12174128)
38. Yamashita F, Ohtani H, Koyabu N, Ushigome F, Satoh H, Murakami H, Uchiumi T, Nakamura T, Kuwano M, Tsujimoto M, et al. (2006) Inhibitory effects of angiotensin II receptor antagonists and leukotriene receptor antagonists on the transport of human organic anion transporter 4. J Pharm Pharmacol 58:1499-1505. (Pubitemid 44785539)